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Introduction
In October 2002, the first patient with CAPS was trea-
ted successfully with the anti-IL-1 agent anakinra at our
Centre in the UK, and in 2009 a nationally funded cana-
kinumab treatment service initiated for CAPS in Eng-
land. By the end of 2012, 82 symptomatic individuals
have been assessed at our Centre.
Objectives
To describe our experience, and outcomes of 82 indivi-
duals with clinical CAPS, including treatment and nat-
ural history.
Methods
We examined all available medical and laboratory records.
Results
Of 82 patients with clinical CAPS a pathogenic sequence
variant (PSV) was detected in 77 (94%); 17 PSVs were
identified, the commonest were R260W (27%), A439V
(23%), T348M (17%), V198M (5%). 5 patients had no
PSV detected on Sanger sequencing: 3 children with
CINCA and 2 patients with adult onset clinical MWS.
90% were white, 8.5% South Asian and 1% African. 46
(56%) gave a positive family history. There were 8
CINCA cases, 4 MWS/CINCA overlap (75% T348M),
59 MWS (62% A439V, 31% R260W, 19% T348M, 5%
V198M) and 11 FCAS (36% A439V, 27% R260W, 9%
V198M). Hearing impairment was present in 31 (38%);
12/14 patients (86%) with T348M, 1/19 (5%) of A439V,
3/22 (14%) of R260W and 3/4 (75%) of V198M.
51 patients are receiving canakinumab (20 having con-
verted from anakinra). Over a median follow up (FU)
period of 28 months (IQR 15-40), 43 (84%) have experi-
enced complete remission (CR) of disease activity whilst
the remainder (8, 16%) have experienced partial remis-
sion (PR), defined as good but incomplete resolution of
symptoms or serum inflammatory markers. 15 (29%)
patients are being treated with double the licensed dose
– 4 CINCA (including 2 children), 4 MWS/CINCA over-
lap, 6MWS (including 2 children) and 1 FCAS with uvei-
tis. 3 patients have discontinued canakinumab and are
currently on no treatment (one each with A439V,
T348M, R260W) due to: an episode of diverticulitis;
pregnancy; a desire for a treatment break. Serious adverse
events included infections (diverticulitis, UTI, tonsillitis).
24 patients are on anakinra and over a median FU of
47 months (IQR 12-72) 20 remain in CR and 4 in PR. 6
patients have previously tried canakinumab; 2 had CR
but were converted due to: planned pregnancy; planned
insertion of a ventricular peritoneal shunt. One adult
CINCA patient with a good PR could not tolerate travel
to our Centre. A female with mutation negative MWS
previously in CR on anakinra opted for a trial of canaki-
numab, but developed a massive disease flare resulting
in hospitalisation. She subsequently reverted to anakinra
and is once again in CR. 2 males (A439V, T346I) dis-
continued canakinumab due to: lack of efficacy; develop-
ment of major systemic inflammation and a morphea
like rash. On anakinra the former remains in PR whilst
the latter has experienced CR.
2 children with mild R260W disease have declined
treatment.
Conclusion
In this series T348M underlies more severe disease than
the other common mutations. A decade of IL-1 block-
ade confirms its efficacy and relative safety in CAPS
across the clinical severity spectrum. Canakinumab is
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the more popular drug due to its long action; however, a
small number of patients are unresponsive to this
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